
CDSCO targets unapproved enclomiphene drugs, compliance ongoing
The story in brief
CDSCO has ordered action against unapproved enclomiphene drugs, which are used to treat male infertility. The DCGI is enforcing compliance, impacting India’s pharmaceutical market. Manufacturers must submit action-taken reports, while unapproved formulations without central safety evaluations are being targeted. Public health experts warn that consuming unapproved drugs can lead to poor treatment outcomes.